Compare SSRM & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSRM | CRSP |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.8B |
| IPO Year | 1997 | 2016 |
| Metric | SSRM | CRSP |
|---|---|---|
| Price | $33.42 | $55.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 22 |
| Target Price | $42.40 | ★ $87.56 |
| AVG Volume (30 Days) | ★ 1.9M | 1.3M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | ★ 243.41 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,629,637,000.00 | $289,590,000.00 |
| Revenue This Year | $41.24 | $1,063.30 |
| Revenue Next Year | $16.20 | $283.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 63.68 | ★ 9169.85 |
| 52 Week Low | $18.19 | $44.12 |
| 52 Week High | $39.44 | $78.48 |
| Indicator | SSRM | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 52.39 |
| Support Level | $28.41 | $50.56 |
| Resistance Level | $33.66 | $60.04 |
| Average True Range (ATR) | 1.15 | 2.83 |
| MACD | -0.58 | -0.03 |
| Stochastic Oscillator | 4.81 | 51.06 |
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.